Completed PHASE3 INTERVENTIONAL 2-arm NCT00334958

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Sponsor: Eisai Inc.

Conditions Epilepsy

Interventions Placebo Rufinamide

Updated 8 times since 2017 Last updated: May 20, 2021 Started: Feb 13, 2006 Primary completion: May 20, 2009 Completion: May 20, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00334958, this PHASE3 trial focuses on Epilepsy and remains completed. Sponsored by Eisai Inc., it has been updated 8 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Sep 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Inc.

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Altoona, United States , Ames, United States , Asheville, United States , Atlanta, United States , Augusta, United States , Baltimore, United States , Boston, United States , Bradenton, United States , Burlington, United States , Canton, United States and 53 more locations